Serina also announced the departure of Remy Gross from its Board of Directors. Mr. Ledger stated, “Remy has been a trusted advisor to the team at Serina for many years. We thank Remy for his ...

BROOKLYN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- All Heart Homecare Agency is proud to announce that it has been named the winner of the Best of Brooklyn 2025 Award for Best Home Health Aides. This ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval our partner Jazz Pharmaceuticals received from the U.S. Food and Drug Administration in 2024 for Ziihera® ...

TELA’s management is scheduled to present at the 2025 Jefferies Global Healthcare Conference at 11:05 am ET on June 5 th, 2025. Interested parties can access the live and archived webcast at ...

Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services ...

Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 ...

Les revenus pour les trois premiers mois de 2025 s’élèvent à 2,8 millions d’euros contre 1,1 millions d’euros pour la même période en 2024. Les revenus des trois premiers mois de 2025 proviennent des ...

Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May 20, 2025 indicating that the Company’s failure to ...

Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated ...

Gyre intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and cash flows from operations, to advance its Phase 2 clinical trial of F351 in metabolic ...

Endurance Bio Inc., a clinical-stage biotechnology company developing therapies for neurodegenerative and metabolic diseases, today announced that its compound, T-168, has been selected for testing on ...

Teva is also increasing the Pool Tender Caps applicable to the Pool 2 Notes and the Pool 3 Notes (each, as defined below) from $250.0 million (equivalent) to $350.0 million (equivalent) and from $200.